Skip to content
Inciteful Med

Treatment Standards: Ensuring You Get Best-in-Class Care

Last updated:

Scleroderma treatment is specific to the organs affected. Standard care involves immunosuppressants like MMF for lung disease, calcium channel blockers for Raynaud's, and ACE inhibitors for renal crises. High-dose steroids require strict monitoring due to the risk of kidney failure.

Key Takeaways

  • • Treatment for scleroderma is organ-specific and often involves a combination of medications to target the lungs, kidneys, skin, and blood vessels.
  • • Mycophenolate mofetil and nintedanib are standard treatments used to slow the progression of interstitial lung disease.
  • • Taking moderate to high doses of corticosteroids significantly increases the risk of a life-threatening scleroderma renal crisis.
  • • ACE inhibitors are the mandatory first-line, life-saving treatment for patients experiencing an active renal crisis.
  • • Deep or spreading localized scleroderma (morphea) requires systemic treatment like methotrexate rather than just topical creams.

Because scleroderma affects many different parts of the body, treatment is “organ-specific.” This means your doctor will likely prescribe a combination of medications to target your lungs, skin, joints, and blood vessels simultaneously. Knowing the standard of care—the treatments that research has proven most effective—empowers you to ensure you are receiving the best possible management [1][2].

Protecting the Lungs (SSc-ILD)

Lung involvement, or Interstitial Lung Disease (ILD), is now the leading cause of concern in systemic sclerosis. Treatment typically focuses on two goals: quieting the overactive immune system and stopping the scarring process [3][1].

  • Immunosuppressants: Mycophenolate mofetil (MMF) is the current first-line standard for slowing lung decline [1][4]. Cyclophosphamide is also used but is often reserved for more severe cases due to its side effects [1].
  • Antifibrotics: Nintedanib is specifically approved to slow the rate of lung scarring [3][5].
  • Biologics: Tocilizumab (an IL-6 inhibitor) is an approved option that helps preserve lung function in certain patients with early, active disease [6][7].

The Renal Safety “Red Line”

One of the most critical safety rules in scleroderma care involves the use of corticosteroids (like Prednisone).

  • The Danger: Research has shown that moderate to high doses of steroids—specifically 15 mg per day or higher—are a major risk factor for triggering Scleroderma Renal Crisis (SRC), a life-threatening spike in blood pressure and kidney failure [8][9][10].
  • The Standard: If your doctor prescribes steroids, they must monitor your blood pressure and kidney function very closely. For a patient in an active Renal Crisis, ACE inhibitors (like lisinopril or enalapril) are the mandatory, life-saving first-line treatment [11][12].

Managing Blood Vessels (Raynaud’s & Ulcers)

The goal of vascular treatment is to keep blood vessels open and prevent painful digital ulcers (sores on the fingertips) [13][14].

  • First-line: Calcium channel blockers (like nifedipine or amlodipine) are commonly used to relax blood vessels [14].
  • Second-line: If Raynaud’s is severe, doctors may add PDE5 inhibitors (like sildenafil) or, in critical cases, intravenous prostanoids to improve blood flow [15][14].

Treating Joint and Muscle Pain

Profound fatigue, aching joints, and muscle stiffness are often the most disabling daily symptoms [16].

  • Immunomodulators: Methotrexate is frequently used early in the disease to treat inflammatory joint pain, muscle pain, and skin thickening [17][18].
  • Physical Therapy: A structured program of stretching and physical therapy is a core component of managing joint stiffness and preventing permanent loss of motion (contractures) [19].

Treating Localized Scleroderma (Morphea)

For patients with morphea, the goal is to stop the spread and prevent permanent skin or joint damage [20][2].

  • Mild/Surface Disease: Potent topical steroids or calcineurin inhibitors (creams) are the first step, often used alongside UVA-1 phototherapy [21][22].
  • Deep or Spreading Disease: If the morphea is linear (in bands) or affects deeper tissue (muscle/fat), the standard of care is Methotrexate, sometimes combined with a short course of systemic steroids [23][22].

Warning Signs of Substandard Care

You should seek a second opinion or a specialist center if:

  1. You are prescribed high-dose steroids (>15 mg/day) without a plan for daily blood pressure monitoring [9].
  2. You have lung scarring (ILD) but have not been offered MMF or Nintedanib [3][1].
  3. You are in a renal crisis but are not immediately started on an ACE inhibitor [11].
  4. Your deep-tissue morphea is being treated only with topical creams, allowing it to spread [2].

Frequently Asked Questions

What is the standard treatment for scleroderma lung disease?
The standard of care for interstitial lung disease in scleroderma includes immunosuppressants like mycophenolate mofetil (MMF) to calm the immune system. Antifibrotic medications like nintedanib are also frequently used to slow down the rate of lung scarring.
Can steroid medications cause a scleroderma renal crisis?
Yes, taking moderate to high doses of corticosteroids—typically 15 mg per day or more—is a major risk factor for triggering scleroderma renal crisis. This is a life-threatening spike in blood pressure, which is why close monitoring is mandatory if steroids are used.
How are Raynaud's and digital ulcers treated in scleroderma?
Doctors typically prescribe calcium channel blockers to relax blood vessels and improve blood flow to the fingers. For severe cases, PDE5 inhibitors or intravenous medications may be used to prevent and heal painful sores on the fingertips.
What is the standard treatment for localized scleroderma (morphea)?
Mild or surface-level morphea is often treated with strong topical steroid creams or UVA-1 light therapy. However, if the disease affects deeper muscle and fat tissues, or is spreading in bands, systemic medications like methotrexate are the standard of care.
What is the treatment for a scleroderma renal crisis?
ACE inhibitors are the mandatory, life-saving first-line treatment for a scleroderma renal crisis. They work to rapidly control blood pressure and protect kidney function during this severe complication.

Questions for Your Doctor

  • • If I have lung involvement, should we consider combining Mycophenolate Mofetil (MMF) with an antifibrotic like Nintedanib?
  • • Is the dose of steroids I'm taking (e.g., Prednisone) putting me at risk for Scleroderma Renal Crisis?
  • • Should I be taking an ACE inhibitor daily as a preventive measure, or only if my blood pressure rises?
  • • For my Raynaud's, would a PDE5 inhibitor (like sildenafil) or a calcium channel blocker be more effective for me?
  • • For my morphea, is it time to move from topical creams to a systemic treatment like Methotrexate or UVA-1 light therapy?

Questions for You

  • • Have you noticed any new, painful sores on your fingertips (digital ulcers) that aren't healing?
  • • How often are you recording your blood pressure at home? (This is the most important 'check' for renal safety).
  • • If you are on Methotrexate, are you able to attend the regular blood tests required to monitor your liver and blood counts?
  • • Is your skin thickening still spreading to new areas, or has it stabilized with your current treatment?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?

    Campochiaro C, Allanore Y, Braun-Moscovici Y, et al.

    Autoimmunity reviews 2024; (23(1)):103439 doi:10.1016/j.autrev.2023.103439.

    PMID: 37690478
  2. 2

    Morphea and Eosinophilic Fasciitis: An Update.

    Mertens JS, Seyger MMB, Thurlings RM, et al.

    American journal of clinical dermatology 2017; (18(4)):491-512 doi:10.1007/s40257-017-0269-x.

    PMID: 28303481
  3. 3

    The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review.

    Al Oweidat KS, Abdulelah AA, Toubasi AA, et al.

    Canadian respiratory journal 2025; (2025()):1682546 doi:10.1155/carj/1682546.

    PMID: 40630797
  4. 4

    Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.

    Fischer A, Patel NM, Volkmann ER

    Open access rheumatology : research and reviews 2019; (11()):283-307 doi:10.2147/OARRR.S226695.

    PMID: 31849543
  5. 5

    Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.

    Lescoat A, Roofeh D, Kuwana M, et al.

    Clinical reviews in allergy & immunology 2023; (64(3)):239-261 doi:10.1007/s12016-021-08891-0.

    PMID: 34468946
  6. 6

    Treatment for systemic sclerosis-associated interstitial lung disease.

    Roofeh D, Lescoat A, Khanna D

    Current opinion in rheumatology 2021; (33(3)):240-248 doi:10.1097/BOR.0000000000000795.

    PMID: 33741803
  7. 7

    Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

    Khanna D, Lin CJF, Furst DE, et al.

    The Lancet. Respiratory medicine 2020; (8(10)):963-974 doi:10.1016/S2213-2600(20)30318-0.

    PMID: 32866440
  8. 8

    ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis.

    Bütikofer L, Varisco PA, Distler O, et al.

    Arthritis research & therapy 2020; (22(1)):59 doi:10.1186/s13075-020-2141-2.

    PMID: 32209135
  9. 9

    [Renal Involvement in Connective Tissue Diseases].

    Weiner SM

    Deutsche medizinische Wochenschrift (1946) 2018; (143(2)):89-100 doi:10.1055/s-0043-106563.

    PMID: 29359289
  10. 10

    Risk factors and outcome of Thai patients with scleroderma renal crisis: a disease duration-matched case control study.

    Wangkaew S, Lertthanaphok S, Puntana S, Noppakun K

    International journal of rheumatic diseases 2017; (20(10)):1562-1571 doi:10.1111/1756-185X.13145.

    PMID: 28752678
  11. 11

    Scleroderma renal crisis.

    Hudson M, Ghossein C, Steen V

    Presse medicale (Paris, France : 1983) 2021; (50(1)):104063 doi:10.1016/j.lpm.2021.104063.

    PMID: 33548376
  12. 12

    ANCA-Associated Vasculitis Co-Occurrence With Systemic Sclerosis: A Case Report of a Rare Diagnostic Dilemma.

    Cheta J, Binder M, Kowalewska J, Magoon S

    Journal of investigative medicine high impact case reports 2018; (6()):2324709618785188 doi:10.1177/2324709618785188.

    PMID: 30083557
  13. 13

    Digital Ulcers and Microvascular Abnormalities Presenting As the Initial Manifestations of Pre-scleroderma.

    Arango A, Yaman RN, Mumtaz S, et al.

    Cureus 2024; (16(12)):e75061 doi:10.7759/cureus.75061.

    PMID: 39759709
  14. 14

    Update of EULAR recommendations for the treatment of systemic sclerosis.

    Kowal-Bielecka O, Fransen J, Avouac J, et al.

    Annals of the rheumatic diseases 2017; (76(8)):1327-1339 doi:10.1136/annrheumdis-2016-209909.

    PMID: 27941129
  15. 15

    High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications.

    Furtado S, Dunogué B, Jourdi G, et al.

    Journal of scleroderma and related disorders 2021; (6(2)):178-186 doi:10.1177/2397198320957558.

    PMID: 35386738
  16. 16

    Exploratory clinical subgroup clustering in systemic sclerosis: Results from the Indian Progressive Systemic Sclerosis Registry.

    Philip SS, Janardana R, Shenoy P, et al.

    Journal of scleroderma and related disorders 2024; (9(1)):29-37 doi:10.1177/23971983231215470.

    PMID: 38333526
  17. 17

    Immunosuppression use in early systemic sclerosis may be increasing over time.

    Park R, Nevskaya T, Baron M, Pope JE

    Journal of scleroderma and related disorders 2022; (7(1)):33-41 doi:10.1177/23971983211000971.

    PMID: 35386940
  18. 18

    Remission rates and risk factors for relapse in pediatric morphea: a multicenter retrospective study of Pediatric Rheumatology Academy (PeRA)-Research Group (RG).

    Bağlan E, Kızıldağ Z, Çağlayan Ş, et al.

    Clinical rheumatology 2023; (42(10)):2855-2860 doi:10.1007/s10067-023-06677-7.

    PMID: 37378874
  19. 19

    The Efficacy of a Home-Based, Self-Administered Hand Exercise Program for Patients With Systemic Sclerosis: A Randomized Controlled, Evaluator-Blind, Clinical Trial.

    Gokcen N, Badak SO, Sarpel T, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2022; (28(2)):e422-e429 doi:10.1097/RHU.0000000000001752.

    PMID: 34030163
  20. 20

    Morphea: a practical review of its diagnosis, classification and treatment.

    Rodríguez-Salgado P, García-Romero MT

    Gaceta medica de Mexico 2019; (155(5)):483-491 doi:10.24875/GMM.M20000336.

    PMID: 32091025
  21. 21

    Effectiveness of PUVA vs. UVA1 phototherapy in the treatment of morphea patients.

    Malewska-Woźniak A, Osmola-Mañkowska A, Adamski Z

    Postepy dermatologii i alergologii 2022; (39(4)):757-761 doi:10.5114/ada.2021.108437.

    PMID: 36090739
  22. 22

    Update on Management of Morphea (Localized Scleroderma) in Children.

    George R, George A, Kumar TS

    Indian dermatology online journal 2020; (11(2)):135-145 doi:10.4103/idoj.IDOJ_284_19.

    PMID: 32477969
  23. 23

    [Localized scleroderma].

    Al-Gburi S, Kreuter A, Moinzadeh P

    Dermatologie (Heidelberg, Germany) 2024; (75(3)):197-207 doi:10.1007/s00105-024-05297-9.

    PMID: 38363312

This page explains scleroderma treatment standards for educational purposes only. Always consult your rheumatologist or specialist to determine the safest and most effective medication plan for your specific symptoms.

Stay up to date

Get notified when new research about Scleroderma is published.

No spam. Unsubscribe anytime.